Zhang Lu, Hui Tian-Li, Wei Yu-Xian, Cao Zhu-Min, Feng Fan, Ren Guo-Sheng, Li Fan
Department of Oncology, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University China.
Department of Endocrine Surgery and Breast Cancer Center, The First Affiliated Hospital of Chongqing Medical University #1 YouYi Road, YuZhong District Chongqing 400016 China
RSC Adv. 2018 Nov 27;8(69):39520-39528. doi: 10.1039/c8ra06017g. eCollection 2018 Nov 23.
PHD Finger Protein 2 (PHF2), as a protein code and a transcription regulatory gene, is a member of the Jumonji-C domain (JmjC). PHF2 is located at human chromosome 9q22.31 and is frequently decreased in various malignancies. However, the definite role of PHF2 in breast cancer remains unclear. To detect the expression and function of PHF2 in breast cancer, a q-PCR assay was used to detect the mRNA expression of PHF2 in breast cancer cell lines and paired breast cancer tissues, and immunohistochemistry was used to test the protein expression in breast cancer tissues and adjacent tissues. In addition, an adenovirus vector system was utilized to upregulate the expression of PHF2 in breast cancer cells. In our study, we found that PHF2 was down-expressed in breast cancer on both the mRNA and protein levels and the low expression of PHF2 was significantly associated with lymph node metastasis, Ki67 positive rate, ER negative expression and poor prognosis in breast cancer patients. The ectopic expression of PHF2 obviously inhibited the proliferation of breast cancer cell lines and the growth of xenograft tumors. Due to the tumor suppressor signature of PHF2 in breast cancer, we have reasons to believe that it could be a promoting marker and target for the prognosis and therapy of breast cancer.
PHD指蛋白2(PHF2)作为一种蛋白质编码和转录调控基因,是Jumonji-C结构域(JmjC)的成员。PHF2位于人类染色体9q22.31,在各种恶性肿瘤中其表达常常降低。然而,PHF2在乳腺癌中的确切作用仍不清楚。为了检测PHF2在乳腺癌中的表达和功能,采用q-PCR检测法检测乳腺癌细胞系和配对乳腺癌组织中PHF2的mRNA表达,并用免疫组织化学法检测乳腺癌组织及癌旁组织中的蛋白表达。此外,利用腺病毒载体系统上调乳腺癌细胞中PHF2的表达。在我们的研究中,我们发现PHF2在mRNA和蛋白水平上在乳腺癌中均低表达,且PHF2的低表达与乳腺癌患者的淋巴结转移、Ki67阳性率、雌激素受体(ER)阴性表达及预后不良显著相关。PHF2的异位表达明显抑制乳腺癌细胞系的增殖和异种移植瘤的生长。鉴于PHF2在乳腺癌中的肿瘤抑制特征,我们有理由相信它可能是乳腺癌预后和治疗的一个促进性标志物及靶点。